You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
麗珠醫藥(01513.HK)獲授凝血(酉每)抑制劑大中華區專利
阿思達克 07-21 09:43
麗珠醫藥(01513.HK)公佈,與華匯拓醫藥簽署《專利及技術轉讓協議》,華匯拓醫藥同意將其研發的HHT120項目在大中華區(中國內地、香港、澳門及臺灣地區)內的所有權利、所有權和權益轉讓並轉移給公司。公司需向華匯拓醫藥支付相應的專利及技術轉讓費用總額最多8,600萬元人民幣(包括首付款、開發里程碑金),以及按協議支付銷售提成。 HHT120是華匯拓醫藥自主研發的一款凝血(酉每)抑制劑,已於去年4月獲國家藥監局批準開展臨牀試驗,首次臨牀試驗適應症擬用於預防骨科大手術術後的靜脈血栓栓塞症。 公司認爲,本次引進HHT120項目是公司拓寬自身治療領域產品的全新佈局,積極佈局具有市場潛力的領域,有助於提高公司的綜合實力,符合公司中長期創新發展的戰略佈局。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account